Baillie Gifford & CO Agios Pharmaceuticals, Inc. Transaction History

Baillie Gifford & CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 06, 2021	BUY	$44.23 - $57.5 $132 - $172	3 Added 1.64%	186 $10,000
Q4 2020 Feb 10, 2021	BUY	$33.21 - $46.54 $6,077 - $8,516	183 New	183 $8,000
Q1 2020 May 08, 2020	SELL	$31.52 - $53.81 $53,867 - $91,961	-1,709 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$30.08 - $50.59 $32.5 Million - $54.7 Million	-1,081,985 Reduced 99.84%	1,709 $82,000
Q3 2019 Nov 07, 2019	BUY	$32.4 - $49.58 $125,226 - $191,626	3,865 Added 0.36%	1,083,694 $35.1 Million
Q2 2019 Aug 08, 2019	BUY	$46.17 - $68.1 $9.59 Million - $14.1 Million	207,604 Added 23.8%	1,079,829 $53.9 Million
Q1 2019 May 01, 2019	BUY	$45.92 - $67.67 $436,699 - $643,541	9,510 Added 1.1%	872,225 $0
Q4 2018 Feb 14, 2019	BUY	$42.73 - $76.53 $8.22 Million - $14.7 Million	192,272 Added 28.68%	862,715 $39.8 Million
Q3 2018 Nov 13, 2018	BUY	$71.67 - $91.95 $3.14 Million - $4.03 Million	43,840 Added 7.0%	670,443 $51.7 Million
Q2 2018 Jul 17, 2018	BUY	$73.22 - $99.55 $3.26 Million - $4.43 Million	44,462 Added 7.64%	626,603 $52.8 Million
Q1 2018 May 10, 2018	BUY	$59.83 - $86.53 $34.8 Million - $50.4 Million	582,141 New	582,141 $47.6 Million

237

57.1M

374K

394K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.83B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.